Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

wockhardt bio pty ltd - apomorphine hydrochloride hemihydrate, quantity: 10 mg/ml - injection, solution - excipient ingredients: sodium metabisulfite; sodium hydroxide; hydrochloric acid; water for injections - apomorphine wockhardt solution for injection or infusion is indicated to reduce the number and severity of ?off? phases in patients with parkinson?s disease severely disabled by motor fluctuations refractory to conventional therapy. initiation of therapy with apomorphine should be undertaken in a specialist unit in a hospital setting. conventional therapy should be continued during ?on? phases.

Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

interpharma pty ltd - apomorphine hydrochloride hemihydrate, quantity: 5 mg/ml - injection, solution - excipient ingredients: sodium metabisulfite; sodium chloride; hydrochloric acid; water for injections - indicated to reduce the number and severity of ?off? phases in patients with parkinson?s disease severely disabled by motor fluctuations refractory to conventional therapy. initiation of therapy with apomorphine should be undertaken in a specialist unit in a hospital setting. conventional therapy should be continued during ?on? phases.

Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

stada pharmaceuticals australia pty ltd - apomorphine hydrochloride hemihydrate, quantity: 50 mg - injection, solution - excipient ingredients: sodium metabisulfite; water for injections; hydrochloric acid - movapo pfs is indicated to reduce the number and severity of "off" phases in patients with parkinson's disease severely disabled by motor fluctuations refractory to conventional therapy. initiation of therapy with apomorphine injection should be undertaken by a specialist unit in a hospital setting. conventional therapy should be continued during "on" phases.

Իռլանդիա - անգլերեն - HPRA (Health Products Regulatory Authority)

pharmaceuticals sales & development sweden ab (pharmswed) - apomorphine hydrochloride hemihydrate - solution for infusion - 5 milligram(s)/millilitre - dopamine agonists; apomorphine

Իռլանդիա - անգլերեն - HPRA (Health Products Regulatory Authority)

evolan pharma ab - apomorphine hydrochloride hemihydrate - solution for infusion - 5 milligram(s)/millilitre - dopamine agonists; apomorphine

Ավստրալիա - անգլերեն - APVMA (Australian Pesticides and Veterinary Medicines Authority)

jurox pty limited - apomorphine hydrochloride - oral tablet - apomorphine hydrochloride alkaloid active 6.5 mg/tb - central nervous system - dog | bitch | castrate | puppy - emetic | induce vomiting

Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

stada pharmaceuticals australia pty ltd - apomorphine hydrochloride hemihydrate, quantity: 50 mg - injection, solution - excipient ingredients: sodium metabisulfite; water for injections; sodium hydroxide; hydrochloric acid - movapo is indicated to reduce the number and severity of "off" phases in patients with parkinson's disease severely disabled by motor fluctuations refractory to conventional therapy. initiation of therapy with movapo should be undertaken by a specialist unit in a hospital setting. conventional therapy should be continued during "on" phases.

Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

stada pharmaceuticals australia pty ltd - apomorphine hydrochloride hemihydrate, quantity: 20 mg - injection, solution - excipient ingredients: sodium metabisulfite; water for injections; sodium hydroxide; hydrochloric acid - movapo is indicated to reduce the number and severity of "off" phases in patients with parkinson's disease severely disabled by motor fluctuations refractory to conventional therapy. initiation of therapy with movapo should be undertaken by a specialist unit in a hospital setting. conventional therapy should be continued during "on" phases.

Ամերիկայի Միացյալ Նահանգներ - անգլերեն - NLM (National Library of Medicine)

trupharma, llc - apomorphine hydrochloride (unii: f39049y068) (apomorphine - unii:n21far7b4s) - apomorphine hydrochloride injection is indicated for the acute, intermittent treatment of hypomobility, "off" episodes ("end-of-dose wearing off" and unpredictable "on/off" episodes) in patients with advanced parkinson's disease. apomorphine hydrocloride inejction has been studied as an adjunct to other medications [see clinical studies (14)] . apomorphine hydrocloride is contraindicated in patients: - using concomitant drugs of the 5ht3 antagonist class including antiemetics (e.g., ondansetron, granisetron, dolasetron, palonosetron) and alosetron [see drug interactions (7.1)] . there have been reports of profound hypotension and loss of consciousness when apomorphine hydrocloride was administered with ondansetron. - with hypersensitivity/allergic reaction to apomorphine or to any of the excipients of apomorphine hydrocloride, including a sulfite (i.e., sodium metabisulfite). angioedema or anaphylaxis may occur [see warnings and precautions (5.12)]. risk summary there are no adequate data on the developmenta

Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

interpharma pty ltd - apomorphine hydrochloride hemihydrate, quantity: 10 mg - injection, solution - excipient ingredients: sodium metabisulfite; water for injections; sodium hydroxide; hydrochloric acid - apomorphine injection is indicated to reduce the number and severity of "off" phases in patients with parkinson's disease severely disabled by motor fluctuations refractory to conventional therapy. initiation of therapy with apomorphine injection should be undertaken by a specialist unit in a hospital setting. conventional therapy should be continued during "on" phases.